Faron Pharmaceuticals (FARN) H1 2025 earnings summary

Executive summary

• Achieved significant clinical and financial milestones in H1 2025, including positive phase II results and full enrollment for bexmarilimab (BEX) in high-risk myelodysplastic syndrome (MDS), and regulatory progress.

• FDA granted a clear path to a seamless, adaptive phase II/III registration trial for BEX in frontline high-risk MDS, with potential for accelerated approval as early as 2028.

• Secured orphan drug designations for bexmarilimab in MDS from both EMA and FDA, enhancing regulatory support and market exclusivity.

• Expanded oncology pipeline with new solid tumor trials and strengthened management and board for business development.

• Presented data at major oncology conferences and published in top-tier journals, highlighting strong clinical progress.

Financial highlights

• Ended H1 2025 with a cash balance of EUR 13.5 million, down from EUR 30.0 million in 2024.

• Operating loss for H1 2025 was EUR -11.9 million, compared to EUR -11.3 million in H1 2024.

• R&D expenses increased to EUR 7.1 million from EUR 6.7 million year-over-year.

• Loss per share improved to EUR 0.18 from EUR 0.20 year-over-year.

• Net assets were EUR -16.7 million at period end, compared to EUR 1.4 million in 2024.

Outlook and guidance

• Phase II/III registration trial for BEX in high-risk MDS to start in H2 2025, with interim analysis for accelerated approval possible in 2028.

• Cash runway extends into Q1 2026, with flexibility to draw additional tranches from the convertible bond arrangement.

• Ongoing partnering discussions, supported by a top-tier investment bank, to maximize shareholder value and explore global and regional deal options.

• Expansion into additional cancer indications, including AML and solid tumors, with multiple new trials planned or initiated.